Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
|Articles|August 24, 2012
GAO: States Spending More on Medicaid Supplemental Payments
Advertisement
States reported a combined $32 billion in supplemental payments to Medicaid providers in 2010, a substantial increase from 2006, according to a report released Monday by the Government Accountabilty Office (GAO), but incomplete reporting by states means the exact amount isn't known.
Medicaid supplemental payments (which are distinct from typical fee-for-service or managed-care costs) are divided into two categories. Disproportionate share hospital (DSH) payments are intended to offset uncompensated care costs for hospitals that serve more low-income and Medicaid patients, and non-DSH payments go to other health-care providers based on criteria set by state officials, but aren't required by federal law.
Read the full story:
Source: Governing
Advertisement
Related to this article
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
Tegoprubart Eases Symptom Burden vs Tacrolimus After Kidney Transplant
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5